Stock Quote - HSM-T
Stock Quote - HSDT
Dane C. Andreeff
President and CEO
Mr. Andreeff is the General Partner and Portfolio Manager of Maple Leaf Partners, L.P. and the President of Andreeff Equity Advisors, L.L.C. Mr. Andreeff has managed investment portfolios since 1996 for Andreeff Equity, L.P., Andreeff Overseas Ltd. and Clover Partners, LP. Prior to managing portfolios, Mr. Andreeff worked as an associate analyst at Furman Selz and Granite Capital International Group. Currently, Mr. Andreeff serves as a Director of TraceSecurity Inc., HDL Therapeutics, Inc. and Myocardial Solutions, Ltd.
Mr. Andreeff received his Master's degree in Economics from the University of Texas at Arlington in 1991 and Bachelor's degree in Economics from the University of Texas at Arlington in 1989.
Jeffrey S. Mathiesen
Chief Financial Officer
Jeff is an accomplished senior executive and director of public and privately held companies with broad experience in the biopharmaceutical, medical device, semiconductor capital equipment and water filtration markets. Mr. Mathiesen has served as Director and Audit Committee Chair of Sun BioPharma, Inc. (OTCMKTS: SNBP), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, since 2015, and was appointed Vice Chair and Lead Independent Director in March 2020. Mr. Mathiesen has also served as Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a publicly traded medical technology company providing neuromodulation continuous EEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders, since 2017, and eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020. Mr. Mathiesen most recently served as CFO and Advisor to the CEO of Teewinot Life Sciences Corporation, a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. He previously served as the CFO of Gemphire Therapeutics Inc., a publicly-held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, and as CFO of Sunshine Heart, Inc., a publicly-held early-stage medical device company, both of which completed successful IPOs and follow-on equity offerings. Mr. Mathiesen has held executive and financial management positions with private and publicly traded companies dating back to 1987. He began his career at Deloitte & Touche LLP. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.
Antonella Favit-Van Pelt, MD, PhD
Chief Medical Officer
A rare disease expert and a pioneer in the field of applied theranostic for the development of disease-modifying treatments. Board-certified Neurologist, she holds a PhD in Pharmacology and presents with more than 20 years of drug development expertise in the pharmaceutical industry and academia. She started her clinical practice activity in 1994 with specialist clinics in Europe where continues her involvement as a specialist consultant managing patients with movement disorders and rare neuromuscular disorders.
Currently serving as Chief Medical Officer at Helius Medical Technologies, she performed, until March 2021, as Head US Medical Strategy for Neurology at Lundbeck and, previously in 2017, as Head of Medical Affairs at Luitpold. In 2013, she founded Synaerion Therapeutics and its affiliate Thera Neuropharma, Inc. (2016), two privately-held biotechnology companies developing a small molecule regenerative therapy and RNAi-based integrated technology platform for ALS and traumatic brain injury (“TBI”), where she oversaw all aspects of the companies’ management and strategy as Chief Executive Officer, President & Chairwoman of the Board from 2014 to 2017 and continues to serve as President & Chairwoman. In 2009, she founded StratMedica, LLC, a privately-held company designed to provide corporate clients with contract senior management support and directed, as Principal from 2009 to 2016, clinical development and medical programs for several healthcare companies, including Johnson & Johnson and Teva. She started her pharmaceutical career in 2001 as Global Clinical Development Lead at GE Healthcare (formerly Amersham Health), then as Director of Medical Strategy at Bristol-Myers Squibb in 2005 and, in 2007, as Senior Director and Global Medical Lead at Shire Pharmaceuticals.
VP of Sales and Marketing, North America
Prior to joining Helius, Mr. Fantazzia worked for LivaNova, PLC, a global medical technology company that designs, develops, manufactures and sells innovative therapeutic solutions in the fields of neuromodulation and cardiovascular disease, from 2016 until 2021. He most recently served as Vice President of North America Sales and Marketing for LivaNova’s Epilepsy business, where he managed all aspects related to its commercialization of a neuromodulation technology for the treatment of drug-resistant epilepsy. During his time with LivaNova/Cyberonics Inc., Mr. Fantazzia also served as Vice President of Global Sales and Marketing for its Neuromodulation segment from 2015 to 2016 and Vice President of U.S. Sales from 2016 to 2018.
Prior to the merger between Sorin S.p.A. and Cyberonics Inc., which combined to form LivaNova in 2015, Mr. Fantazzia worked for Cyberonics Inc. (Nasdaq: CYBX) a medical device company with core expertise in neuromodulation. He joined the company as a Regional Sales Manager in 2005, and subsequently held a series of positions of increasing responsibility, culminating in his promotion to Vice President of Global Sales and Marketing for Neuromodulation in 2015.
Mr. Fantazzia holds a B.S. in Business Administration from Villanova University.
Dr. Sackier joined the Company in December of 2014 as Chief Medical Officer and brings to his role extensive experience in new technologies and treatment methodologies gained over more than 30 years in the healthcare industry. He is widely recognized as one of the leaders of the laparoscopic surgery revolution. A trained surgeon, Jonathan Sackier has collaborated with pharmaceutical and medical device technology partners including ConvaTec, Pfizer, Karl Storz, Applied Medical, Stryker, Siemens, Bayer and Novartis. He helped build several companies including medical technology, research and product-design and medical contract sales organizations. In addition to his role as CMO, Dr. Sackier has been a Visiting Professor of Surgery at the Nuffield Department of Surgical Sciences at Oxford University since 2014. From 2005 to 2014, Dr. Sackier was a Visiting Professor of Surgery at University of Virginia and prior to that a Clinical Professor at George Washington University in Washington, DC. from 1995 to 1999 when he ceased clinical affiliation but retained his academic affiliation. Dr. Sackier founded and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer in 1995. Prior, he worked to develop and market the AESOP robot with Computer Motion from 1992 to 1998 when that company went through a successful IPO in 1997.
Dr. Sackier currently sits on the board of directors of Kypha (since 2014 and was Chairman of that board from 2014-2016), Clinvue (since 2010), and Brandon Medical (since 2009), is a Trustee of First Star and previously chaired The Larry King Cardiac Foundation Board of Governors. Dr. Sackier was also Director for Hemoshear from 2008 to 2015 and served as Chairman of Adenosine Therapeutics which became part of Clinical Data and then Forest Laboratories from 2002 to 2008. He has also served as a board member of The American College of Surgeons Foundation, The Surgical Fellowship Foundation and Rex Bionics, winner of London’s 2014 Aim Award for outstanding achievement for most successful growth market.
VP, General Manager, Canadian Operations
Mark has spent the last 20 years in the Healthcare space, primarily in the MedTech areas of Cardiology and Neurology. He has led commercial and clinical teams for several Fortune 500 companies. While at Johnson & Johnson Medical, Mark held commercial roles of increasing responsibility in Canada leading teams. While at J&J, he led several pan-Canadian commercial launches related to new technologies that included both capital equipment and consumable products. While at Boston Scientific, he was charged with creating the Canadian electrophysiology go-to-market strategy and developing the commercial team. Prior to coming into the healthcare sector, Mark spent 12 years in corporate marketing, communications and business development for the Toronto Blue Jays and National Hockey League. He is a graduate of Ohio University (BSc) and resides in Toronto with his family.